Primary Chemotherapy in Patients With HER2-positive Early Breast Cancer

NCT01172223 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

81

Enrollment

OTHER

Sponsor class

Conditions

Breast Cancer

Interventions

DRUG: Myocet (Non-pegylated liposomal doxorubicin (NPLD))
DRUG: Paclitaxel
DRUG: Lapatinib (GW572016, Tykerb)

Sponsor

Prof Dirk Elling